{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T23:39:16Z","timestamp":1792539556827,"version":"4.5.0"},"reference-count":72,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Affective Disorders"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.jad.2026.121240","type":"journal-article","created":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T16:02:54Z","timestamp":1769875374000},"page":"121240","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Adverse events related to buspirone: a real-world pharmacovigilance study using the FAERS database"],"prefix":"10.1016","volume":"401","author":[{"given":"Zujun","family":"Wen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingxing","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jad.2026.121240_bb0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.ntt.2023.107318","article-title":"Exposure to the pharmaceutical buspirone alters locomotor activity, anxiety-related behaviors, and transcripts related to serotonin signaling in larval zebrafish (Danio rerio)","volume":"101","author":"Biju","year":"2024","journal-title":"Neurotoxicol. Teratol."},{"key":"10.1016\/j.jad.2026.121240_bb0010","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyg.2021.639198","article-title":"Insomnia - a heterogenic disorder often comorbid with psychological and somatic disorders and diseases: a narrative review with focus on diagnostic and treatment challenges","volume":"12","author":"Bjorvatn","year":"2021","journal-title":"Front. Psychol."},{"issue":"1","key":"10.1016\/j.jad.2026.121240_bb0015","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0193-953X(05)70209-4","article-title":"Pharmacologic treatment of generalized anxiety disorder","volume":"24","author":"Brawman-Mintzer","year":"2001","journal-title":"Psychiatr. Clin. North Am."},{"issue":"6","key":"10.1016\/j.jad.2026.121240_bb0020","first-page":"347","article-title":"Seizures associated with buspirone overdose: case report and literature review","volume":"21","author":"Catalano","year":"1998","journal-title":"Clin. Neuropharmacol."},{"issue":"7","key":"10.1016\/j.jad.2026.121240_bb0025","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26073081","article-title":"The involvement of serotonin in the obesity pathway-a last decade systematic review of the literature","volume":"26","author":"C\u00eempeanu","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jad.2026.121240_bb0030","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/978-1-4684-5952-4_35","article-title":"Effects of tryptophan and of 5-hydroxytryptamine receptor subtype agonists on feeding","volume":"294","author":"Curzon","year":"1991","journal-title":"Adv. Exp. Med. Biol."},{"issue":"7","key":"10.1016\/j.jad.2026.121240_bb0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e28918","article-title":"Side effects and cognitive benefits of buspirone: a systematic review and meta-analysis","volume":"10","author":"Du","year":"2024","journal-title":"Heliyon"},{"issue":"2","key":"10.1016\/j.jad.2026.121240_bb0040","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/BF01578749","article-title":"A metabolite of buspirone increases locus coeruleus activity via alpha 2-receptor blockade","volume":"76","author":"Engberg","year":"1989","journal-title":"J. Neural Transm."},{"issue":"3","key":"10.1016\/j.jad.2026.121240_bb0045","doi-asserted-by":"crossref","first-page":"239","DOI":"10.3758\/CABN.8.3.239","article-title":"Anxiety and cognitive efficiency: differential modulation of transient and sustained neural activity during a working memory task","volume":"8","author":"Fales","year":"2008","journal-title":"Cogn. Affect. Behav. Neurosci."},{"issue":"3","key":"10.1016\/j.jad.2026.121240_bb0050","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/j.1476-5381.1990.tb12961.x","article-title":"The involvement of 5-hydroxytryptaminergic and dopaminergic mechanisms in the eating induced by buspirone, gepirone and ipsapirone","volume":"99","author":"Fletcher","year":"1990","journal-title":"Br. J. Pharmacol."},{"issue":"6","key":"10.1016\/j.jad.2026.121240_bb0055","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1124\/dmd.110.032094","article-title":"Selection of alternative CYP3A4 probe substrates for clinical drug interaction studies using in vitro data and in vivo simulation","volume":"38","author":"Foti","year":"2010","journal-title":"Drug Metab. Dispos."},{"issue":"1","key":"10.1016\/j.jad.2026.121240_bb0060","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.pediatrneurol.2014.09.017","article-title":"A randomized double-blind placebo-controlled clinical trial of adjuvant buspirone for irritability in autism","volume":"52","author":"Ghanizadeh","year":"2015","journal-title":"Pediatr. Neurol."},{"issue":"2","key":"10.1016\/j.jad.2026.121240_bb0065","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/j.1526-4610.2009.01575.x","article-title":"Triptans, serotonin agonists, and serotonin syndrome (serotonin toxicity): a review","volume":"50","author":"Gillman","year":"2010","journal-title":"Headache"},{"issue":"1","key":"10.1016\/j.jad.2026.121240_bb0070","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.eurpsy.2003.10.002","article-title":"Generalized anxiety disorder and major depressive disorder comorbidity: an example of genetic pleiotropy?","volume":"19","author":"Gorwood","year":"2004","journal-title":"Eur. Psychiatry"},{"issue":"11","key":"10.1016\/j.jad.2026.121240_bb0075","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3928\/02793695-20151022-01","article-title":"Buspirone: back to the future","volume":"53","author":"Howland","year":"2015","journal-title":"J. Psychosoc. Nurs. Ment. Health Serv."},{"issue":"18","key":"10.1016\/j.jad.2026.121240_bb0080","first-page":"1618","article-title":"Combination of serotonergic agents resulted in severe adverse effects","volume":"101","author":"J\u00e4gestedt","year":"2004","journal-title":"Lakartidningen"},{"key":"10.1016\/j.jad.2026.121240_bb0085","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.jad.2023.11.025","article-title":"Safety assessment of Brexpiprazole: real-world adverse event analysis from the FAERS database","volume":"346","author":"Jiang","year":"2024","journal-title":"J. Affect. Disord."},{"issue":"6","key":"10.1016\/j.jad.2026.121240_bb0090","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1177\/02698811241249651","article-title":"Unveiling potential adverse events associated with escitalopram oxalate: a real-world analysis based FDA adverse event reporting system database","volume":"38","author":"Jiang","year":"2024","journal-title":"J. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.jad.2026.121240_bb0095","doi-asserted-by":"crossref","first-page":"360","DOI":"10.21873\/invivo.13836","article-title":"Evaluation of times-to-onset and outcomes of lung adverse events associated with Sorafenib using JADER","volume":"39","author":"Kanbayashi","year":"2025","journal-title":"In Vivo"},{"issue":"Suppl. 1","key":"10.1016\/j.jad.2026.121240_bb0100","article-title":"Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders","volume":"14","author":"Katzman","year":"2014","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.jad.2026.121240_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.yfrne.2022.101010","article-title":"Sex hormone fluctuation and increased female risk for depression and anxiety disorders: from clinical evidence to molecular mechanisms","volume":"66","author":"Kundakovic","year":"2022","journal-title":"Front. Neuroendocrinol."},{"issue":"2","key":"10.1016\/j.jad.2026.121240_bb0110","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1177\/070674379403900217","article-title":"Sustained bradycardia during fluvoxamine and buspirone intoxication","volume":"39","author":"Langlois","year":"1994","journal-title":"Can. J. Psychiatr."},{"key":"10.1016\/j.jad.2026.121240_bb0115","doi-asserted-by":"crossref","DOI":"10.2196\/46538","article-title":"Challenges and implications for menopausal health and help-seeking behaviors in midlife women from the United States and China in light of the COVID-19 pandemic: web-based panel surveys","volume":"10","author":"Lau","year":"2024","journal-title":"JMIR Public Health Surveill."},{"issue":"15","key":"10.1016\/j.jad.2026.121240_bb0120","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1001\/jama.2023.2428","article-title":"A review of anxiety disorders","volume":"329","author":"Leichsenring","year":"2023","journal-title":"Jama"},{"key":"10.1016\/j.jad.2026.121240_bb0125","first-page":"1","article-title":"Vitreoretinal traction syndrome, nitrituria and human epidermal growth factor receptor negative might occur in the aromatase-inhibitor anastrozole treatment","volume":"2024","author":"Li","year":"2024","journal-title":"Int. J. Clin. Pract."},{"issue":"23","key":"10.1016\/j.jad.2026.121240_bb0130","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1016\/0024-3205(90)90378-5","article-title":"Selective increase in carbohydrate intake by rats treated with 8-hydroxy-2-(di-n-propylamino)-tetraline or buspirone","volume":"46","author":"Luo","year":"1990","journal-title":"Life Sci."},{"issue":"3","key":"10.1016\/j.jad.2026.121240_bb0135","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1001\/archgenpsychiatry.2010.2","article-title":"Overweight, obesity, and depression: a systematic review and meta-analysis of longitudinal studies","volume":"67","author":"Luppino","year":"2010","journal-title":"Arch. Gen. Psychiatry"},{"issue":"1\u20132","key":"10.1016\/j.jad.2026.121240_bb0140","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/BF01292626","article-title":"Serotonin (5-HT) release in the dorsal raph\u00e9 and ventral hippocampus: raph\u00e9 control of somatodendritic and terminal 5-HT release","volume":"103","author":"Matos","year":"1996","journal-title":"J. Neural Transm. (Vienna)"},{"key":"10.1016\/j.jad.2026.121240_bb0145","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.18247","article-title":"Locus coeruleus to basolateral amygdala noradrenergic projections promote anxiety-like behavior","volume":"6","author":"McCall","year":"2017","journal-title":"Elife"},{"issue":"5","key":"10.1016\/j.jad.2026.121240_bb0150","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/0006-3223(94)90035-3","article-title":"Effects of buspirone on plasma prolactin and cortisol levels in major depressed and normal subjects","volume":"35","author":"Meltzer","year":"1994","journal-title":"Biol. Psychiatry"},{"issue":"6","key":"10.1016\/j.jad.2026.121240_bb0155","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1177\/1559827617716376","article-title":"Appetite regulation: hormones, peptides, and neurotransmitters and their role in obesity","volume":"13","author":"Miller","year":"2019","journal-title":"Am. J. Lifestyle Med."},{"issue":"9","key":"10.1016\/j.jad.2026.121240_bb0160","article-title":"A comprehensive review of the generalized anxiety disorder","volume":"15","author":"Mishra","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.jad.2026.121240_bb0165","doi-asserted-by":"crossref","DOI":"10.1177\/2398212820930321","article-title":"The role of the locus coeruleus in the generation of pathological anxiety","volume":"4","author":"Morris","year":"2020","journal-title":"Brain Neurosci. Adv."},{"issue":"5","key":"10.1016\/j.jad.2026.121240_bb0170","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1111\/j.1365-2710.2012.01344.x","article-title":"Probable drug-drug interaction leading to serotonin syndrome in a patient treated with concomitant buspirone and linezolid in the setting of therapeutic hypothermia","volume":"37","author":"Morrison","year":"2012","journal-title":"J. Clin. Pharm. Ther."},{"issue":"1","key":"10.1016\/j.jad.2026.121240_bb0175","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-22814-8","article-title":"The effect of obesity on the availabilities of dopamine and serotonin transporters","volume":"8","author":"Nam","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jad.2026.121240_bb0180","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.2147\/NDT.S107178","article-title":"Risk factors for suicide among patients with schizophrenia: a cohort study focused on cerebrospinal fluid levels of homovanillic acid and 5-hydroxyindoleacetic acid","volume":"12","author":"Neider","year":"2016","journal-title":"Neuropsychiatr. Dis. Treat."},{"issue":"5","key":"10.1016\/j.jad.2026.121240_bb0185","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1089\/g4h.2023.0050","article-title":"Effects of cooperative, competitive, and solitary exergames on cognition and anxiety levels in children with developmental disabilities","volume":"12","author":"Nekar","year":"2023","journal-title":"Games Health J."},{"issue":"12 Pt 2","key":"10.1016\/j.jad.2026.121240_bb0190","first-page":"100","article-title":"The side effect profile of buspirone in comparison to active controls and placebo","volume":"43","author":"Newton","year":"1982","journal-title":"J. Clin. Psychiatry"},{"issue":"3b","key":"10.1016\/j.jad.2026.121240_bb0195","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/0002-9343(86)90327-X","article-title":"Review of the side-effect profile of buspirone","volume":"80","author":"Newton","year":"1986","journal-title":"Am. J. Med."},{"issue":"12","key":"10.1016\/j.jad.2026.121240_bb0200","article-title":"Neurological insights: transient unilateral relative afferent pupillary defect in the context of serotonin syndrome","volume":"16","author":"Nichols","year":"2024","journal-title":"Cureus"},{"issue":"4","key":"10.1016\/j.jad.2026.121240_bb0205","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.pnpbp.2007.02.010","article-title":"Effects of cytochrome P450 (CYP) 3A4 inhibitors on the anxiolytic action of tandospirone in rat contextual conditioned fear","volume":"31","author":"Nishikawa","year":"2007","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.jad.2026.121240_bb0210","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2023.1136557","article-title":"Depression symptoms, anxiety, and stress among undergraduate entrance admission seeking students in Bangladesh: a cross-sectional study","volume":"11","author":"Rabby","year":"2023","journal-title":"Front. Public Health"},{"issue":"3","key":"10.1016\/j.jad.2026.121240_bb0215","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1177\/00185787241311138","article-title":"Severe hypertension on the background of Buspirone use","volume":"60","author":"Rafique","year":"2025","journal-title":"Hosp. Pharm."},{"issue":"4","key":"10.1016\/j.jad.2026.121240_bb0220","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/j.1755-5949.2010.00160.x","article-title":"Antidepressant-induced suicidality: an update","volume":"16","author":"Reeves","year":"2010","journal-title":"CNS Neurosci. Ther."},{"issue":"12 Pt 2","key":"10.1016\/j.jad.2026.121240_bb0225","first-page":"11","article-title":"Pharmacology and neurochemistry of buspirone","volume":"43","author":"Riblet","year":"1982","journal-title":"J. Clin. Psychiatry"},{"issue":"5","key":"10.1016\/j.jad.2026.121240_bb0230","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1001\/archpsyc.1988.01800290060008","article-title":"Long-term treatment of anxiety and risk of withdrawal. prospective comparison of clorazepate and buspirone","volume":"45","author":"Rickels","year":"1988","journal-title":"Arch. Gen. Psychiatry"},{"issue":"6","key":"10.1016\/j.jad.2026.121240_bb0235","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1016\/S0149-2918(03)80159-5","article-title":"A review of the efficacy and tolerability of immediate-release and extended-release formulations of gepirone","volume":"25","author":"Robinson","year":"2003","journal-title":"Clin. Ther."},{"issue":"7","key":"10.1016\/j.jad.2026.121240_bb0240","doi-asserted-by":"crossref","first-page":"796","DOI":"10.7150\/ijms.6048","article-title":"Data mining of the public version of the FDA Adverse Event Reporting System","volume":"10","author":"Sakaeda","year":"2013","journal-title":"Int. J. Med. Sci."},{"issue":"5","key":"10.1016\/j.jad.2026.121240_bb0245","doi-asserted-by":"crossref","first-page":"461","DOI":"10.7150\/ijms.7967","article-title":"Commonality of drug-associated adverse events detected by 4 commonly used data mining algorithms","volume":"11","author":"Sakaeda","year":"2014","journal-title":"Int. J. Med. Sci."},{"key":"10.1016\/j.jad.2026.121240_bb0250","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.889088","article-title":"Generalised weibull model-based approaches to detect non-constant hazard to signal adverse drug reactions in longitudinal data","volume":"13","author":"Sauzet","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"5","key":"10.1016\/j.jad.2026.121240_bb0255","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1097\/PSY.0000000000000691","article-title":"Illness anxiety disorder: psychopathology, epidemiology, clinical characteristics, and treatment","volume":"81","author":"Scarella","year":"2019","journal-title":"Psychosom. Med."},{"issue":"5a","key":"10.1016\/j.jad.2026.121240_bb0260","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/0002-9343(87)90197-5","article-title":"Evaluation of the safety and side effects of antianxiety agents","volume":"82","author":"Schnabel","year":"1987","journal-title":"Am. J. Med."},{"key":"10.1016\/j.jad.2026.121240_bb0265","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.parkreldis.2020.10.020","article-title":"A trial of buspirone for anxiety in Parkinson\u2019s disease: safety and tolerability","volume":"81","author":"Schneider","year":"2020","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.jad.2026.121240_bb0270","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajp.2021.102711","article-title":"Cerebrospinal fluid monoamine metabolite concentrations in suicide attempt: a meta-analysis","volume":"62","author":"Sharma","year":"2021","journal-title":"Asian J. Psychiatr."},{"issue":"8","key":"10.1016\/j.jad.2026.121240_bb0275","doi-asserted-by":"crossref","first-page":"796","DOI":"10.30773\/pi.2020.0017","article-title":"Efficacy of buspirone augmentation of escitalopram in patients with major depressive disorder with and without atypical features: a randomized, 8 week, multicenter, open-label clinical trial","volume":"17","author":"Shin","year":"2020","journal-title":"Psychiatry Investig."},{"key":"10.1016\/j.jad.2026.121240_bb0280","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.jad.2025.03.017","article-title":"The real-world safety profile of sertraline: pharmacovigilance analysis of the FAERS database","volume":"379","author":"Shu","year":"2025","journal-title":"J. Affect. Disord."},{"issue":"3","key":"10.1016\/j.jad.2026.121240_bb0285","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1002\/(SICI)1520-6394(1999)9:3<131::AID-DA5>3.0.CO;2-H","article-title":"Meta-analysis of the safety and tolerability of two dose regimens of buspirone in patients with persistent anxiety","volume":"9","author":"Sramek","year":"1999","journal-title":"Depress. Anxiety"},{"issue":"24","key":"10.1016\/j.jad.2026.121240_bb0290","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1001\/jama.2022.22744","article-title":"Anxiety disorders: a review","volume":"328","author":"Szuhany","year":"2022","journal-title":"Jama"},{"key":"10.1016\/j.jad.2026.121240_bb0295","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.jad.2024.02.055","article-title":"Patterns of unhealthy lifestyle and their associations with depressive and anxiety symptoms among Chinese young adults: a latent class analysis","volume":"352","author":"Tang","year":"2024","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2026.121240_bb0300","first-page":"15","article-title":"Biological basis for the formation of suicidal behavior: a review","volume":"39","author":"Tatayeva","year":"2025","journal-title":"Med. J. Islam Repub. Iran"},{"issue":"8","key":"10.1016\/j.jad.2026.121240_bb0305","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S2215-0366(24)00222-0","article-title":"Global burden of disease 2021: mental health messages","volume":"11","author":"The Lancet P","year":"2024","journal-title":"Lancet Psychiatry"},{"issue":"1","key":"10.1016\/j.jad.2026.121240_bb0310","doi-asserted-by":"crossref","first-page":"54","DOI":"10.5694\/j.1326-5377.1989.tb136355.x","article-title":"Buspirone overdose","volume":"150","author":"Tiller","year":"1989","journal-title":"Med. J. Aust."},{"issue":"1","key":"10.1016\/j.jad.2026.121240_bb0315","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/0014-2999(84)90696-4","article-title":"Buspirone increases locus coeruleus noradrenergic neuronal activity in vitro","volume":"106","author":"Trulson","year":"1984","journal-title":"Eur. J. Pharmacol."},{"issue":"10","key":"10.1016\/j.jad.2026.121240_bb0320","doi-asserted-by":"crossref","first-page":"48","DOI":"10.17116\/jnevro202312310148","article-title":"Gender characteristics of anxiety disorders","volume":"123","author":"Vasenina","year":"2023","journal-title":"Zh. Nevrol. Psikhiatr. Im. S S Korsakova"},{"issue":"4","key":"10.1016\/j.jad.2026.121240_bb0325","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1111\/andr.13533","article-title":"A real-world pharmacovigilance study of FDA adverse event reporting system events for sildenafil","volume":"12","author":"Wang","year":"2024","journal-title":"Andrology"},{"issue":"11","key":"10.1016\/j.jad.2026.121240_bb0330","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s11920-021-01290-4","article-title":"Correlates of quality of life in anxiety disorders: review of recent research","volume":"23","author":"Wilmer","year":"2021","journal-title":"Curr. Psychiatry Rep."},{"issue":"4","key":"10.1016\/j.jad.2026.121240_bb0335","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1080\/17425255.2023.2219390","article-title":"A real-world data analysis of topotecan in the FDA Adverse Event Reporting System (FAERS) database","volume":"19","author":"Yang","year":"2023","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"issue":"31","key":"10.1016\/j.jad.2026.121240_bb0340","doi-asserted-by":"crossref","DOI":"10.3346\/jkms.2024.39.e226","article-title":"Psychotropic medications promote time-dependent reduction of suicidal ideation in mood disorder: a prospective cohort study","volume":"39","author":"Yang","year":"2024","journal-title":"J. Korean Med. Sci."},{"issue":"6","key":"10.1016\/j.jad.2026.121240_bb0345","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1080\/17425255.2023.2235267","article-title":"A real-world data analysis of acetylsalicylic acid in FDA Adverse Event Reporting System (FAERS) database","volume":"19","author":"Zhao","year":"2023","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.jad.2026.121240_bb0350","article-title":"A real-world disproportionality analysis of Everolimus: data mining of the public version of FDA adverse event reporting system","volume":"15","author":"Zhao","year":"2024","journal-title":"Front. Pharmacol."},{"issue":"11","key":"10.1016\/j.jad.2026.121240_bb0355","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1080\/14740338.2024.2410436","article-title":"A real-world pharmacovigilance study using disproportionality analysis of United States Food and Drug Administration Adverse Event Reporting System events for vinca alkaloids: comparing vinorelbine and Vincristine","volume":"23","author":"Zhong","year":"2024","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.jad.2026.121240_bb0360","doi-asserted-by":"crossref","DOI":"10.1155\/da\/4178541","article-title":"Global, regional, and national trends in the burden of anxiety disorders from 1992 to 2021: an age-period-cohort analysis based on the Global Burden of Disease Study 2021","volume":"2025","author":"Zhou","year":"2025","journal-title":"Depress. Anxiety"}],"container-title":["Journal of Affective Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032726000911?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032726000911?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T04:21:00Z","timestamp":1782188460000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165032726000911"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":72,"alternative-id":["S0165032726000911"],"URL":"https:\/\/doi.org\/10.1016\/j.jad.2026.121240","relation":{},"ISSN":["0165-0327"],"issn-type":[{"value":"0165-0327","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adverse events related to buspirone: a real-world pharmacovigilance study using the FAERS database","name":"articletitle","label":"Article Title"},{"value":"Journal of Affective Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jad.2026.121240","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"121240"}}